# Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

> **NCT06514898** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Florida** · enrollment: 12 (estimated)

## Conditions studied

- Recurrent Group 3 Medulloblastoma
- Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma

## Interventions

- **BIOLOGICAL:** TTRNA-DC vaccines with GM-CSF
- **BIOLOGICAL:** TTRNA-xALT
- **DRUG:** Td vaccine
- **BIOLOGICAL:** autologous HSCs
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06514898
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-05
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06514898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06514898, "Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06514898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*